Brief: CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy
29/04/2025 07:04
April 29 (Reuters) - CSL Ltd CSL.AX: CSL VIFOR AND TRAVERE THERAPEUTICS ANNOUNCE STANDARD EU APPROVAL FOR FILSPARI® IN IGA NEPHROPATHY Source text: ID:nPnjfpg1a Further company coverage: CSL.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule